+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Guillain-Barre Syndrome Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987013
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence


  • Akari Therapeutics PLC
  • Bayer AG
  • Biotest AG
  • CSL Limited
  • Grifols S A
  • Kedrion Biopharma Inc
  • MORE
The Guillain-Barre syndrome market studied was anticipated to grow with a CAGR of nearly 5.2% during the forecast period owing to the rising prevalence of the Guillain-Barre syndrome. The major factors attributing to the growth of the GBS market are increasing geriatric population leading to the prevalence of immune disorders like multiple sclerosis, Acute Motor Axonal Neuropathy, and others. Furthermore, rise in infections due to Epstein–Barr virus, Zika virus, and others, due to the resultant higher demand for treatment. For instance, according to the Foundation for Peripheral Neuropathy report published in 2019, GBS affects about 3,000-6,000 people each year in the United States fueling the demand for the effective treatment which is expected to drive the global GBS market during the forecast period.

Key Market Trends

Intravenous Immunoglobulins are Expected to Hold the Largest Market Share in the Global Guillain-Barre Syndrome Market
  • The Intravenous immunoglobulins are expected to account for the largest share in the market which can be attributed to availability of wide range of IVIG products such as Gamunex, Gammagard, and Privigen in the market and increased adoption of treatment by off-label use of intravenous immunoglobulins due to rising prevalence of multifocal motor neuropathy, dermatomyositis, polymyositis, stiff person syndrome, and relapsing-remitting multiple sclerosis. Furthermore, the rise in early approvals by regulatory agencies for intravenous immunoglobulin (IVIG) products along with rising government support to increase plasma yield are likely to drive the market during the forecast period.
  • Based on Distribution Channel, hospital pharmacies account for the highest revenue in the market due to increased preference for the patients owing to the prevalence of hospital-associated cases. Furthermore, increased access to specialty care products, pathological products, and clinical examinations, diagnosis of GBS at a single premise are best possible in hospitals indicate an exponential growth of the segment global GBS market.
North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall GBS market throughout the forecast period. The dominance is due to several factors such as increasing geriatric population who are more prone to infections due to decreased immunity leading to high demand for effective therapy in the region. For instance, according to the report published by the Centers for Disease Control & Prevention (CDC) in December 2019, people of any age group can develop GBS, but the prevalence of GBS is at increases in the people aged over 50 years which necessitates huge demand due to presence of huge geriatric population in the US. Also, the presence of key pharmaceutical companies investing in the research activities to develop novel products and the regulatory bodies such as USFDA which create awareness about the disease and treatment are likely to attribute to the growth of the market in the region propelling the global GBS market revenue in the forecast period.

Competitive Landscape

The global Guillain-Barre syndrome market is moderately competitive and consists of several major players. Few of the prominent players currently dominating the market are applying various strategies like acquiring the products or other companies to consolidate their market positions across the globe and while others are applying for Investigational New Drug (IND) application approvals with huge product pipelines coupled with government initiatives to increase plasma yield. For example, in September 2019, Akari Therapeutics Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases has received orphan drug designation for nomacopan from the U.S. Food and Drug Administration (FDA) which was successfully proven efficient to treat Guillain-Barre syndrome in animals models driving the market growth. Some of the companies which are currently dominating the market are Grifols S A, CSL Limited, Octapharma AG, Kedrion Biopharma Inc and Takeda Pharmaceutical Company Limited.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Akari Therapeutics PLC
  • Bayer AG
  • Biotest AG
  • CSL Limited
  • Grifols S A
  • Kedrion Biopharma Inc
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study




4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Prevalence of GBS and Geriatric Population
4.2.2 Rise in New Product Approvals due to Accelerated Drug Approval Initiative by USFDA
4.3 Market Restraints
4.3.1 Higher Challenges in Development Stage and Expensive Patented Products
4.3.2 Lack of Awareness of Disease and Effective Treatment in the Developing Economies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5.1 by Therapeutics
5.1.1 Intravenous Immunoglobulin
5.1.2 Plasma Exchange
5.1.3 Others
5.2 by Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.3 by Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles
6.1.1 CSL Limited
6.1.2 Takeda Pharmaceutical Company Limited
6.1.3 Grifols S A
6.1.4 Octapharma AG
6.1.5 Bayer AG
6.1.6 Kedrion Biopharma Inc
6.1.7 Nihon Pharmaceutical Co Ltd
6.1.8 China Biologic Products Holdings Inc
6.1.9 Akari Therapeutics PLC
6.1.10 Biotest AG

Note: Product cover images may vary from those shown
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Grifols S A
  • Octapharma AG
  • Bayer AG
  • Kedrion Biopharma Inc
  • Nihon Pharmaceutical Co Ltd
  • China Biologic Products Holdings Inc
  • Akari Therapeutics PLC
  • Biotest AG
Note: Product cover images may vary from those shown